Lucentis

( ARTG ) Lucentis (ranibizumab) is indicated in adults for:, the treatment of neovascular (wet) age-related macular degeneration (AMD), the treatment of visual impairment due to diabetic macular oedema (DME), treatment of proliferative diabetic retinop‍‍‍‍‍‍​​​‍​​​​​​athy (PDR), the treatment of visual impairment due to choroidal neovascularisation (CNV), the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).,Lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.